NYSE · Healthcare · Financials
Abbott Laboratories (ABT) Financial Statements: Income, Balance Sheet & Cash Flow
Revenue, profitability, balance-sheet strength, and cash generation for ABT. SEC filings, statements through Mar 31, 2026.
Section freshness
Prices as of Sep 4, 4:04 PM EDT · Fundamentals checked Sep 8, 3:20 AM EDT · Statements Mar 31, 2026
Financial read
ABT latest financial snapshot.
Start with the latest reported values below. Deeper quarterly and annual statement tables follow when supplied.
Revenue
$11.16B
+7.8% YoY
Net income
$1.08B
-39.4% QoQ
Free cash flow
$916.00M
-65.1% QoQ
Net margin
9.65%
Operating margin 12.05%
Balance sheet coverage
ABT balance sheet summary
Assets, liabilities, liquidity, debt, and equity sit beside income and cash-flow tables so the statement history reads as one model-ready dataset.
20 quarterly · 4 annual rows · Market data source · as of 2026-03-31
Latest period
Q1 FY2026
20 quarterly · 4 annual rows
Assets / liabilities
$110.43B
Liabilities —
Cash / debt
$6.80B
Net cash -$27.24B
Equity / working capital
$52.06B
Working capital $7.13B
Financial statements
ABT statement coverage.
Income statement, balance sheet, and cash-flow figures for ABT, with quarterly and annual history in the tables below.
Data last updated
Mar 30, 2026
Income periods
24
Balance-sheet periods
24
Cash-flow periods
24
Quarterly and annual ABT statements, sourced from SEC filings, statements through Mar 31, 2026.
Financial statement period
ABT statement history
SEC filings, statements through Mar 31, 2026 · Data last updated: Mar 30, 2026
Income statement
Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.
| Period | Revenue | Operating income | Net income | Net margin | Revenue QoQ | Net income QoQ |
|---|---|---|---|---|---|---|
| Q1 FY2026 | $11.16B | $1.34B | $1.08B | 9.65% | -2.6% | -39.4% |
| Q4 FY2025 | $11.46B | $2.25B | $1.78B | 15.50% | +0.8% | +8.0% |
| Q3 FY2025 | $11.37B | $2.06B | $1.64B | 14.46% | +2.0% | -7.6% |
| Q2 FY2025 | $11.14B | $2.05B | $1.78B | 15.97% | +7.6% | +34.3% |
| Q1 FY2025 | $10.36B | $1.69B | $1.32B | 12.79% | -5.6% | -85.6% |
| Q4 FY2024 | $10.97B | $1.91B | $9.23B | 84.10% | +3.2% | +460.7% |
| Q3 FY2024 | $10.63B | $1.86B | $1.65B | 15.48% | +2.5% | +26.4% |
| Q2 FY2024 | $10.38B | $1.67B | $1.30B | 12.55% | +4.1% | +6.3% |
Balance sheet
Balance-sheet history for assets, liabilities, liquidity, debt, equity, and shares outstanding.
| Period | Cash | Current assets | Current liabilities | Total assets | Total debt | Total equity | Debt QoQ |
|---|---|---|---|---|---|---|---|
| Q1 FY2026 | $6.80B | $25.51B | $18.38B | $110.43B | $34.05B | $52.06B | +163.3% |
| Q4 FY2025 | $8.52B | $26.00B | $16.50B | $86.71B | $12.93B | $52.13B | -0.1% |
| Q3 FY2025 | $7.51B | $24.84B | $14.58B | $84.18B | $12.94B | $50.95B | -3.7% |
| Q2 FY2025 | $6.95B | $24.47B | $13.44B | $84.00B | $13.44B | $50.56B | +1.5% |
| Q1 FY2025 | $6.53B | $23.15B | $13.00B | $81.45B | $13.24B | $48.81B | -6.3% |
| Q4 FY2024 | $7.62B | $23.66B | $14.16B | $81.41B | $14.13B | $47.66B | -5.7% |
| Q3 FY2024 | $7.56B | $23.80B | $14.90B | $74.36B | $14.98B | $39.80B | +1.5% |
| Q2 FY2024 | $6.99B | $23.12B | $13.76B | $73.02B | $14.75B | $39.32B | +1.2% |
Cash flow
Operating cash generation, capital expenditure, free cash flow, buybacks, dividends, and cash movement.
| Period | Operating cash flow | CapEx | Free cash flow | Net income | Buybacks | FCF QoQ |
|---|---|---|---|---|---|---|
| Q1 FY2026 | $1.31B | $399.00M | $916.00M | $1.08B | $180.00M | -65.1% |
| Q4 FY2025 | $3.31B | $689.00M | $2.63B | $1.78B | $302.00M | +14.6% |
| Q3 FY2025 | $2.79B | $496.00M | $2.29B | $1.64B | $305.00M | +48.3% |
| Q2 FY2025 | $2.05B | $502.00M | $1.54B | $1.78B | $6.00M | +65.6% |
| Q1 FY2025 | $1.42B | $484.00M | $933.00M | $1.32B | $280.00M | -56.6% |
| Q4 FY2024 | $2.87B | $720.00M | $2.15B | $9.23B | $315.00M | -0.0% |
| Q3 FY2024 | $2.71B | $556.00M | $2.15B | $1.65B | $751.00M | +50.6% |
| Q2 FY2024 | $1.96B | $533.00M | $1.43B | $1.30B | $3.00M | +127.6% |
Valuation and returns
- Enterprise value
- $214.70B
- TECHi computed
- Return on equity
- 12.06%
- Market data source · as of 2026-09-08
- Return on assets
- 5.68%
- Market data source · as of 2026-09-08
- Debt / equity
- 0.65
- Current ratio 1.39
Ratio values use provider-attributed fields when available and otherwise fall back to TECHi statement math from the visible rows on this page.
Annual revenue and income multiples
Annual sales and income multiple reads use the latest annual statement when available, then fall back to trailing-twelve-month statement math from the visible quarterly rows.
- Annual revenue base
- $44.33B
- Annual statement 2025-12-31
- Annual income base
- $6.52B
- Annual statement 2025-12-31
- Market cap / annual revenue
- 4.23
- Live market value divided by annual revenue
- Market cap / annual income
- 28.73
- Live market value divided by annual net income
Annual sales and income multiple
Market capitalization bridge
TTM valuation multiples
- TTM revenue
- $45.13B
- Trailing twelve months
- TTM EBIT
- $7.71B
- TTM operating income
- Market cap / TTM revenue
- 4.15
- Live market value divided by trailing twelve months revenue
- EV / TTM revenue
- 4.76
- Enterprise value divided by trailing twelve months revenue
Live market value is matched against trailing-twelve-month statement bases first so the multiple moves with the tape instead of anchoring to stale fiscal-year rows.
Profit multiples
Revenue, net income, and free cash flow
Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.
Efficiency
- Revenue / employee
- $369,950.82
- 122,000 employees
- Net income / employee
- $51,442.623
- TTM net income divided by employees
- FCF / employee
- $60,475.41
- TTM free cash flow divided by employees
- Market cap / employee
- $1.54M
- Live value per employee
Growth vs cost pressure
Cash conversion
TTM free cash flow / TTM operating income
Quarterly margin heatmap
Latest quarter expense mix
Profit bridge
Other income statement lines
Balance sheet · Q1 FY2026
- Cash & equivalents
- $6.80B
- Total debt
- $34.05B
- Net cash
- -$27.24B
- Net debt position
- Total equity
- $52.06B
Balance sheet detail
- Current assets
- $25.51B
- Current liabilities
- $18.38B
- Inventory
- $6.99B
- Receivables
- $8.21B
- Property, plant & equipment
- $12.38B
- Current debt
- $4.41B
- Long-term debt
- $29.64B
Debt and liquidity
Cash + short-term investments + receivables / current liabilities
Cash generation
- Operating cash flow
- $1.31B
- Capital expenditure
- $399.00M
- Free cash flow
- $916.00M
- Capital returned
- $180.00M
- Buybacks + dividends paid
Cash-flow detail
- Investing cash flow
- -$20.32B
- Financing cash flow
- $17.31B
- Stock issuance
- $116.00M
- Common stock issued
- Buybacks
- $180.00M
- Net buybacks
- $64.00M
- Repurchases less stock issuance
Cash flow read
ABT converts most of its earnings into cash.
Free cash flow of $916.00M versus $1.08B of reported net income means accruals aren't doing much heavy lifting — the cash is showing up alongside the earnings. That's the cleanest profile a fundamentals desk wants to see.
Frequently asked
Common questions.
What financial data is available for ABT?
TECHi shows Abbott Laboratories's income statement, balance sheet, and cash-flow statement by reported period, with each figure attributed to its source. Line items the company does not report are left blank rather than estimated.
How current are ABT's financial statements?
Each ABT statement is labelled with its reported period and source, so you can see exactly which quarter or fiscal year a figure covers and when the data was last updated.
What is Abbott Laboratories's reported net margin?
Abbott Laboratories reports a net margin of 13.91% in its latest available fundamentals; the statements below show the revenue and cost lines behind it.